Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial
European Urology Focus · 2026-10 · 12 (5) · 866-869
DOI: 10.1016/j.euf.2026.05.017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Louise Kostos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbou…. Hauptthemen laut MEDLINE: Radioisotopes, Lutetium, Radium, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 10 Literaturangaben. Gefördert von: National Health and Medical Research Council, Peter MacCallum Cancer Centre, Peter MacCallum Foundation.
Abstract (Originalsprache)
The integration of [177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy into the treatment paradigm for advanced prostate cancer has improved survival and quality of life; however, resistance and disease progression remain inevitable. Radionuclide combination strategies, particularly α-/β-emitter pairings, aim to overcome biological and dosimetric limitations of [177Lu]Lu-PSMA monotherapy. The AlphaBet trial demonstrated the feasibility and safety of combining the bone-seeking α-emitter radium-223 with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer, underpinned by complementary spatial targeting and radiophysical properties. Ongoing studies are evaluating other novel combinations to overcome resistance, earlier integration to define optimal sequencing, and biomarker-driven approaches to refine patient selection. For patients, these strategies may enable more effective and durable treatments by combining different types of targeted radiation or systemic therapies; however, further studies are needed to confirm long-term benefits and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: louise.kostos@petermac.…
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Can…
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Förderung
- National Health and Medical Research Council
- Peter MacCallum Cancer Centre
- Peter MacCallum Foundation
- Prostate Cancer Foundation
- University of Melbourne
- Australian Cancer Research Foundation
Zitieren
APA
Kostos, L., Buteau, J. P., Azad, A. A., & Hofman, M. S. (2026). Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial. European Urology Focus, 12(5), 866-869. https://doi.org/10.1016/j.euf.2026.05.017
Vancouver
Kostos L, Buteau JP, Azad AA, Hofman MS. Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial. European Urology Focus. 2026;12(5):866-869. doi:10.1016/j.euf.2026.05.017
BibTeX
@article{Kostos2026,
author = {Kostos, Louise and Buteau, James P and Azad, Arun A and Hofman, Michael S},
title = {Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {5},
pages = {866--869},
doi = {10.1016/j.euf.2026.05.017}
}
EUVIMED